Avanir's Main Product Is Nuedexta
Avanir (AVNR) is a small (~$500M market cap) pharmaceutical company that develops and sells drugs for central nervous system disorders. It has two drugs on the market, Nuedexta and Abreva, and a couple in the pipeline. In the company's most recently reported quarterly results released December 10, Nuedexta, which has a gross margin of 94.3%, accounted for 93% of Avanir's total net revenue. It grossed $91.2 million in revenue for the year, representing more than 100% growth on a year-over-year basis. Nuedexta will become even more important to Avanir this spring, as the company will stop recognizing revenue from its only other approved product, Abreva, when its patent expires in...
Only subscribers can access this article, which is part of the PRO research library covering 3,553 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: